EGAGenomicsIllumina HiSeq 2500;ILLUMINAhttps://ega-archive.org/datasets/EGAD000010039896EGA dataset EGAD00001003989EGAVasp, VASP, DmelCG15112, ENHANCER OF ATNSI ACTIVITY, Data Set, MENA, NDPP1, l(2)02029, Enb, enb, ENA, Ena, CG15112, 2018., ENA/VASPKinase Kinases, l(2)k06503, whole exome, MEKs, MAPKK7, DSORT, dsor1, MAP-ERK Kinase, PhrB photolyase activity, xcdk4, MAPK-ERK Kinase, D-MEK/Dsor, cdk4/6, MEK1/2, Pk?7, photoreactivating enzyme activity, PRKMK7, pigmented epithelium, Malignant, D-mek, Mutations, melanoma (disease), melanoma, cdk, resistance, Dmek, Su(Raf)34B, 3, stratum pigmentosa retinae, Kinase, NUP96, JNKK2, epithelium, CG15793, MAP, Map, treatment, average, MAPK ERK Kinase, MOS3, deoxyribocyclobutadipyrimidine pyrimidine-lyase activity, Biopsies, MAPKKs, MAPK-ERK Kinases, PRECOCIOUS, CG5072, MKK7, Naevocarcinoma, Tissue, pigmented retina, inhibiteur, F23A5.3, PSK-J3, MEK 7, D-sor, DSor1, DSOR1, DNA cyclobutane dipyrimidine photolyase activity, SUPPRESSOR OF AUXIN RESISTANCE 3, Map Kinase, Map Kinase Kinase, cdk4, inhibidor, Kinase Kinase, Clients, CMM3, dCdk4, disease management, Therapies, CDK4, SOR, dSor1, Sor, D-Mek, D-MEK, l(2)05428, F23A5_3, inhibitors, Therapy, PRE, SAPKK4, Mitogen-Activated Protein Kinase Kinase, sor/MEK1, MAP-ERK, D-sor-1, malignant, deoxyribonucleic cyclobutane dipyrimidine photolyase activity, DSor, inhibitor, Malignant Melanomas, sor, Client, DRODSOR1, MK, l(2)s4639, MEK/Dsor1, Melanomas, MODIFIER OF SNC1, Melanoma, MAPK ERK Kinases, retinal pigment, MAPK, Malignant Melanoma, MAP Kinase Kinases, deoxyribonucleic photolyase activity, dipyrimidine photolyase (photosensitive), MEK, Mek, MAP Kinase, DMEK-1, simple tissue, DmCdk4, Mitogen Activated Protein Kinase Kinase, retinal pigment layer, dSor, D-SOR, D-Sor, EK1-1, antagonists, DmelCG15793, RPE, resistance., MAPKK, MAP ERK Kinase, Mitogen Activated Protein Kinase Kinases, photolyase activity, Kinases, mek, SAPKK-4, patient, Cdk4/6, Crk3, DmelCG5072, Treatments, p. pigmentosa retinae, dMEK, 8-6, CDK4/6, phr A photolyase activity, DNA-photoreactivating enzyme, Patient, MAPK-ERK, antagonists and inhibitors, Therapeutic, l(2)0671, Dsor, Pk53C, malignant melanoma, Treatment, deoxyribonucleate pyrimidine dimer lyase (photosensitive), MAPK Kinase, l(2)sh0671, MAPK Kinasesfalseena-DATASET-UTMDACC-27-02-2018-23:18:56:158-888 - samplesLongitudinal biopsies from a melanoma patient who initially responded to MEK plus CDK4/6 inhibitor therapy were whole exome sequenced to identify potential resistance mutations. The biopsies included normal tissue, pre-treatment, on-treatment, and several post-resistance timepoints.2018-03-02 10:50:59EGAD000010039899606EGAC00001000839EGAS00001002846